Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CTEV
CTEV logo

CTEV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
26.600
Open
25.630
VWAP
24.70
Vol
111.12K
Mkt Cap
449.11M
Low
23.295
Amount
2.75M
EV/EBITDA(TTM)
8.80
Total Shares
16.97M
EV
5.03B
EV/OCF(TTM)
42.91
P/S(TTM)
0.45
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
Show More

Events Timeline

(ET)
2026-05-07
06:40:00
Claritev Q1 Revenue $244.7M, Exceeds Expectations
select
2026-05-07
06:40:00
FY26 Revenue Consensus at $990.02M
select
2026-02-23 (ET)
2026-02-23
16:20:00
Sees FY26 Adjusted EBITDA at $605M-$615M
select
2026-02-23
16:20:00
Claritev Reports Q4 Revenue of $246.6M
select
2026-01-21 (ET)
2026-01-21
08:20:00
Claritev Forms Strategic Relationship with Kinetiq Health
select

News

seekingalpha
9.5
05-07seekingalpha
PinnedClaritev Corporation Q1 2026 Earnings Call Insights
  • Strong Contract Value: Claritev secured over $40 million in annual contract value bookings in Q1 2026, supporting its sales target of $80 million to $100 million for the year, indicating robust demand and growth potential in the market.
  • Revenue and EBITDA Growth: The company reported total revenue of $244.7 million for the quarter, a 5.8% year-over-year increase, while adjusted EBITDA reached $146.9 million, up 3.4%, demonstrating ongoing improvements in profitability and operational efficiency.
  • Cash Flow Performance: Despite generating $36.8 million in unlevered free cash flow, the company utilized $92.5 million in free cash flow, with management expecting Q1 and Q3 to be cash consumption quarters, while Q2 and Q4 are anticipated to be cash-generating, reflecting seasonal cash flow challenges.
  • Market Expansion and New Clients: The agreement with GDIT to provide a custom network for the World Trade Center Health Program signifies entry into a new public sector market, further enhancing its strategic position in diversified business operations.
seekingalpha
9.5
05-07seekingalpha
Claritev Reports Q1 2026 Financial Results with Mixed Performance
  • Financial Performance: Claritev's Q1 2026 GAAP EPS of -$4.41 missed expectations by $0.34, indicating ongoing profitability challenges, while revenue of $244.7 million beat estimates by $6.11 million, suggesting positive revenue growth amidst difficulties.
  • Net Loss Analysis: The net loss of $73.6 million for Q1 2026 increased from $71.3 million in Q1 2025, reflecting challenges in cost control and profitability that could impact investor confidence moving forward.
  • Adjusted EBITDA Growth: The adjusted EBITDA for Q1 2026 was $146.9 million, a 3.4% increase year-over-year, indicating improvements in operational efficiency, although the overall financial performance remains concerning.
  • Cash Flow Situation: Net cash used in operating activities reached $45.8 million in Q1 2026, up from $30.1 million in Q1 2025, with free cash flow at -$92.5 million, highlighting pressures in cash flow management that may affect future investment capabilities.
seekingalpha
9.5
05-06seekingalpha
Claritev Scheduled to Announce Q1 Earnings on May 7
  • Earnings Announcement: Claritev is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimated at $1.38 and revenue projected at $238.59 million, providing crucial financial health indicators for investors.
  • Revenue Guidance: The company outlines a revenue target of $980 million to $1 billion by 2026, indicating strong growth potential amid accelerating digital transformation, which may attract increased investor interest in its long-term prospects.
  • Rating Upgrade: Claritev's combination of compounding debt and stabilization of its legacy business has led analysts to upgrade its rating, reflecting market confidence in its improving financial condition, which could positively impact its stock price.
  • Market Dynamics: As Claritev approaches its earnings release, companies like Amerigo and Allianz are viewed as strong buys, while Ashford Hospitality and Hudson Pacific lag, highlighting varying investor confidence across different firms.
Newsfilter
3.5
04-30Newsfilter
Claritev Achieves Significant Progress in Healthcare AI
  • Leadership Recognition: Claritev's Chief AI Officer, Fernando Schwartz, has been named to the 2026 DataIQ 100 North America list, highlighting the company's impactful application of data and AI in healthcare, thereby enhancing its industry reputation.
  • AI Integration in Workflows: Schwartz focuses on operationalizing AI to improve coding accuracy and identify performance patterns, enabling healthcare organizations to gain actionable insights at scale, which significantly enhances financial performance.
  • Accelerated Digital Transformation: Michael Kim, Claritev's Chief Digital Officer, notes that Schwartz's leadership is accelerating the company's digital transformation, ensuring that AI technologies are embedded directly into the most critical workflows to improve overall operational efficiency.
  • Strategic Vision: President Travis Dalton emphasizes that AI is a critical driver of Claritev's strategy, aiming to leverage advanced analytics and AI to deliver measurable impacts for clients and the broader healthcare system, promoting transparency and affordability in healthcare.
Newsfilter
8.5
03-25Newsfilter
Claritev Launches Rural Health Grant Program
  • Foundation Launch: Claritev Corporation has established the Claritev Cares™ charitable foundation, aimed at expanding healthcare access through its Rural Health Grant program, with applications open until June 1, 2026, expected to support over 100 rural health initiatives.
  • Significant Historical Contributions: Since 1995, Claritev has donated over $700,000 to underserved communities, supporting the expansion of essential services in hospitals and rural health clinics, demonstrating the company's long-term commitment to community health.
  • Far-reaching Funding Impact: The 2024 Rural Health Grant recipient, New River Health Association, reported that the funding allowed them to increase patient care visits and introduce additional diagnostic services, significantly enhancing the quality of healthcare in their community.
  • Global Influence Expansion: Claritev Cares also made a $10,000 donation to World Central Kitchen, reflecting the company's commitment to supporting communities globally, thereby enhancing its strategic impact on healthcare accessibility.
Benzinga
2.0
03-05Benzinga
Middle East Conflict Heightens Market Uncertainty
  • Escalating Market Risks: The closure of the Strait of Hormuz disrupts approximately 20% of global oil and LNG flows, tightening insurance markets and prompting panic selling among investors, thereby exacerbating overall economic uncertainty.
  • Insider Buying Signals: Prior to the escalation of conflict, insiders at companies like CoStar Group, Hamilton Lane, Vornado Realty Trust, and Claritev Corporation made significant purchases, indicating their confidence in the long-term prospects of these firms, especially during turbulent market conditions.
  • Real Estate Market Recovery Expectations: Despite a brutal reset in the commercial real estate market, insider buying at CoStar Group suggests confidence in the normalization of future transaction activity, potentially driving a rebound in this sector.
  • Stability in Healthcare Technology: Insider purchases at Claritev Corporation before the conflict indicate that, despite heightened geopolitical risks, demand in the healthcare technology sector remains robust, expected to sustain stable cash flows and market positioning.
Wall Street analysts forecast CTEV stock price to rise
3 Analyst Rating
Wall Street analysts forecast CTEV stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Barclays
Overweight
initiated
$28
AI Analysis
2026-04-24
Reason
Barclays
Price Target
$28
AI Analysis
2026-04-24
initiated
Overweight
Reason
Barclays initiated coverage of Claritev with an Overweight rating and $28 price target. With the shares down 70% from the peak in September, Claritev's risk/reward skews positive, the analyst tells investors in a research note. The firm believes the company's recent operational momentum is underappreciated in consensus estimates and finds the stock's valuation attractive at current levels.
Citi
Daniel Grosslight
Buy
downgrade
$63 -> $21
2026-02-25
Reason
Citi
Daniel Grosslight
Price Target
$63 -> $21
2026-02-25
downgrade
Buy
Reason
Citi analyst Daniel Grosslight lowered the firm's price target on Claritev to $21 from $63 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CTEV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Claritev Corp (CTEV.N) is 0.00, compared to its 5-year average forward P/E of -3.40. For a more detailed relative valuation and DCF analysis to assess Claritev Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.40
Current PE
0.00
Overvalued PE
-2.18
Undervalued PE
-4.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.23
Current EV/EBITDA
9.22
Overvalued EV/EBITDA
9.94
Undervalued EV/EBITDA
8.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.62
Current PS
0.43
Overvalued PS
0.92
Undervalued PS
0.32

Financials

AI Analysis
Annual
Quarterly

Whales Holding CTEV

H
HBK Investments L.P.
Holding
CTEV
+3.41%
3M Return
T
Third Point LLC
Holding
CTEV
+3.28%
3M Return
T
The Public Investment Fund of The Kingdom of Saudi Arabia
Holding
CTEV
-5.43%
3M Return
G
GIC Special Investments Pte. Ltd.
Holding
CTEV
-7.53%
3M Return
H
Hellman & Friedman LLC
Holding
CTEV
-9.39%
3M Return
A
Ares Management LLC
Holding
CTEV
-14.69%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Claritev Corp (CTEV) stock price today?

The current price of CTEV is 24.21 USD — it has decreased -8.54

What is Claritev Corp (CTEV)'s business?

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

What is the price predicton of CTEV Stock?

Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is62.00 USD with a low forecast of 33.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Claritev Corp (CTEV)'s revenue for the last quarter?

Claritev Corp revenue for the last quarter amounts to 244.68M USD, increased 5.77

What is Claritev Corp (CTEV)'s earnings per share (EPS) for the last quarter?

Claritev Corp. EPS for the last quarter amounts to -4.41 USD, increased 0.68

How many employees does Claritev Corp (CTEV). have?

Claritev Corp (CTEV) has 3000 emplpoyees as of May 08 2026.

What is Claritev Corp (CTEV) market cap?

Today CTEV has the market capitalization of 449.11M USD.